Background: The early detection of Fabry nephropathy is of interest to us. Its treatment is more effective in early stages. It has been studied by analysing molecular and tissue biomarkers. These have certain disadvantages that hinder its routine use. The aim of this study is to describe the role of the nephrologist in the diagnosis of the disease, and to describe the clinical variables associated with nephropathy in affected patients.

Material And Methods: Cross-sectional study. Patients were included from three reference centres in Argentina.

Results: Seventy two patients were studied (26.26±16.48years): 30 of which (41.6%) were men and 42 of which (58.4%) were women; 27 paediatric patients and 45 adults. Fourteen "index cases" were detected, 50% of which were diagnosed by nephrologists. Nephropathy was found in 44 patients (61%): 6 paediatric patients and 38 adults. Two types of clinical variables were associated with nephropathy: (i)peripheral nervous system compromise (P≤.001), angiokeratomas (P≤.001) and auditory compromise (P=.01-.001), with these being early clinical manifestations of the most severe disease phenotype, and (ii)structural heart disease (P=.01-.001) and central nervous system compromise (P=.05-.01), which are major and late complications, responsible for increased morbidity and mortality and lower life expectancy.

Conclusion: The nephrologist plays an important role in the diagnosis of Fabry nephropathy, although the detection thereof owing to its renal involvement would represent a late diagnosis, because nephropathy is associated with late complications of the most severe disease phenotype.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nefro.2018.10.017DOI Listing

Publication Analysis

Top Keywords

fabry nephropathy
12
clinical variables
12
variables associated
12
role nephrologist
8
associated nephropathy
8
paediatric patients
8
patients adults
8
nervous system
8
system compromise
8
severe disease
8

Similar Publications

Artificial intelligence (AI) is increasingly used in many medical specialties. However, nephrology has lagged in adopting and incorporating machine learning techniques. Nephrology is well positioned to capitalize on the benefits of AI.

View Article and Find Full Text PDF

Genetic Assessment of Living Kidney Transplant Donors: A Survey of Canadian Practices.

Can J Kidney Health Dis

January 2025

Multiorgan Transplant Program, Division of Nephrology, Department of Medicine, McGill University Health Centre, Montreal, QC, Canada.

Background: Kidney failure is a prevalent condition with tendency for familial clustering in up to 27% of the affected individuals. Living kidney donor (LKD) transplantation is the optimal treatment option; however, in Canada, more than 45% of LKDs are biologically related to their recipients which subjects recipients to worse graft survival and donors to higher future risk of kidney failure. Although not fully understood, this observation could be partially explained by genetic predisposition to kidney diseases.

View Article and Find Full Text PDF

Clinical management of female patients with Fabry disease based on expert consensus.

Orphanet J Rare Dis

January 2025

Department of Nephrology and Endocrinology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

Fabry disease is an X-linked lysosomal storage disorder that causes accumulation of glycosphingolipids in body tissues and fluids, leading to progressive organ damage and life-threatening complications. It can affect both males and females and can be classified into classic or later-onset phenotypes. The disease severity in females ranges from asymptomatic to the more severe, classic phenotype.

View Article and Find Full Text PDF

Background: Fabry disease is a rare X-linked multisystem disease, with progressive proteinuric kidney disease contributing significantly to morbidity and mortality of these patients. Evidence shows that sodium-glucose cotransporter 2 inhibitors (SGLT2Is) can reduce proteinuria and slow progression to end-stage kidney disease in both diabetic and non-diabetic kidney disease.

Aim: Evaluate the effects of SGLT2I on kidney function and albuminuria in patients with Fabry disease.

View Article and Find Full Text PDF
Article Synopsis
  • Fabry disease can lead to chronic kidney disease (CKD) due to accumulated sphingolipids causing kidney damage, impacting treatment and prognostic planning.
  • In a study of 405 Fabry patients, significant findings included that 60.5% received treatments, 29.7% had cardiovascular events, and 3.3% reached end-stage kidney disease (ESKD), with men facing higher risks.
  • Key indicators for CKD development included older age, history of cardiovascular issues, specific medication use, and higher urine albumin-to-creatinine ratios, highlighting the need for monitoring even in patients with normal kidney function.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!